Constitutively active μ-opioid receptors

Methods in Enzymology

Volumn 484, Issue C, 2010, Pages 445-469

  Connor, Mark ^a   Traynor, John ^b  

^a MACQUARIE UNIVERSITY   (Australia)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CALCIUM CHANNEL; CHLORNALTREXAMINE; CYPRODIME; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; DIPRENORPHINE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; MORPHINE; MU OPIATE RECEPTOR; MUTANT PROTEIN; NALOXONE; NALTREXOL; NALTREXONE; NALTRINDOLE;

AMINO ACID SUBSTITUTION; BOOK; CARBOXY TERMINAL SEQUENCE; DRUG EFFECT; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; TREATMENT WITHDRAWAL;

EID: 78049397086     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381298-8.00022-8     Document Type: Chapter

References (73)

1. Bagley E.E., Chieng B.C.H., Christie M.J., Connor M. Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine. Br. J. Pharmacol. 2005, 146:68-76.
2. Bagley E.E., Gerke M.B., Vaughan C.W., Hack S.P., Christie M.J. GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal. Neuron 2005, 45:433-445.
3. Beedle A.M., McRory J.E., Poirot O., Doering C.J., Altier C., Barrere C., Hamid J., Nargeot J., Bourinet E., Zamponi G.W. Agonist-independent modulation of N-type calcium channels by ORL1 receptors. Nat. Neurosci. 2004, 7:118-125.
4. Borgland S.L., Connor M., Christie M.J. Nociceptin inhibits calcium channel currents in a subpopulation of small nociceptive trigeminal ganglion neurons in mouse. J. Physiol. 2001, 536:35-47.
5. Bourinet E., Soong T.W., Stea A., Snutch T.P. Determinants of the G protein-dependent opioid modulation of neuronal calcium channels. Proc. Natl. Acad. Sci. USA. 2001, 93:1486-1491.
6. Breivogel C.S., Walker J.M., Huang S.M., Roy M.B., Childers S.R. Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. Neuropharmacology 2004, 47:81-91.
7. Brillet K., Kieffer B.L., Massotte D. Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: Characterization of a tool for inverse agonist screening. BMC Pharmacol. 2003, 3:14.
8. 3 ): Elevated basal signalling activity. Biochem. J. 2000, 348:531-537.
9. Cerione R.A., Codina J., Benovic J.L., Lefkowitz R.J., Birnbaumer L., Caron M.G. The mammalian β2-adrenergic receptor: Reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. Biochemistry 1984, 23:4519-4525.
10. V 2.1 (P/Q-type) channels. J. Gen. Physiol. 2007, 129:385-401.
11. + channels in dendrites of hippocampal CA1 pyramidal neurons. J. Neurosci. 2005, 25:3787-3792.
12. Chieng B., Christie M.J. Local opioid withdrawal in rat single periaqueductal gray neurons in vitro. J. Neurosci. 1996, 16:7128-7136.
13. Christie M.J., Williams J.T., North R.A. Cellular mechanisms of opioid tolerance: Studies in single brain neurons. Mol. Pharmacol. 1987, 32:633-638.
14. Clark M.J., Traynor J.R. Assays for G-protein-coupled receptor signaling using RGS-insensitive Galpha subunits. Meth. Enzymol. 2004, 389:155-169.
15. Colecraft H.M., Brody D.L., Yue D.T. G-protein inhibition of N- and P/Q-type calcium channels: Distinctive elementary mechanisms and their functional impact. J. Neurosci. 2001, 21:1137-1147.
16. Connor M. Shadows across μ-star? Constitutively active μ-opioid receptors revisited. Br. J. Pharmacol. 2009, 156:1041-1043.
17. Connor M., Borgland S.L., Christie M.J. Continued morphine modulation of calcium channel currents in acutely isolated locus coeruleus neurons from morphine-dependent rats. Br. J. Pharmacol. 1999, 128:1561-1569.
18. Connor M., Christie M.J. Modulation of calcium channel currents of acutely dissociated rat periaqueductal grey neurons. J. Physiol. 1998, 509:47-58.
19. Costa T., Herz A. Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. USA 1989, 86:7321-7325.
20. Dascal N. Ion-channel regulation by G proteins. Trends Endocrinol. Metab. 2001, 12:391-398.
21. 35 S]GTPγS scintillation proximity assay: A powerful emerging technique for analysis of GPCR pharmacology. Trends Pharmacol. Sci. 2004, 25:400-401.
22. Divin M.F., Bradbury F.A., Carroll F.I., Traynor J.R. Neutral antagonist activity of naltrexone and 6β-naltrexol in naive and opioid-dependent C6 cells expressing a μ-opioid receptor. Br. J. Pharmacol. 2009, 156:1044-1053.
23. Dobrev D., Friedrich A., Voight N., Jost N., Wettwer E., Christ T., Knaut M., Ravens U. The G protein-gated potassium current IK, ACH is constitutively active in patients with chronic atrial fibrillation. Circulation 2005, 112:3697-3706.
24. 2+ current in excitable cells. Trends Neurosci. 1996, 19:35-43.
25. + channel. J. Gen. Physiol. 1995, 106:1-23.
26. Guo J., Ikeda S.R. Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. Mol. Pharmacol. 2004, 65:665-674.
27. 35 S]GTPgammaS binding assay: Approaches and applications in pharmacology. Life Sci. 2003, 74:489-508.
28. 2+ channels by G-protein βγ subunits. Nature 1996, 380:258-262.
29. Horswill J.G., Bali U., Shaaban S., Kelly J.F., Jeevaratnam P., Babbs A.J., Reynet A.J., In P.W.K. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br. J. Pharmacol. 2007, 152:805-814.
30. Howlett A.C. Efficacy in CB1 receptor-mediated signal transduction. Br. J. Pharmacol. 2004, 142:1209-1218.
31. Huang P., Li J., Chen C., Visiers I., Weinstein H., Liu-Chen L.Y. Functional role of a conserved motif in TM6 of the rat mu opioid receptor: Constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochemistry 2001, 40:13501-13509.
32. Ikeda S.R. Voltage-dependent modulation of N-type calcium channels by G-protein βγ subunits. Nature 1996, 380:255-258.
33. Johnson E.A., Oldfield S., Brakstor E., Gonzalez-Cuello A., Couch D., Hall K.J., Mundell S.J., Bailey C.P., Kelly E., Henderson G. Agonist-selective mechanisms of μ-opioid receptor desensitization in human embryonic kidney 293 cells. Mol. Pharmacol. 2006, 70:676-685.
34. Kara E., Strange P. Use of the [35S]GTPγS binding assay to determine ligand efficacy at G-protein coupled receptors. Protein-Coupled Receptors: Essential Methods 2010, Wiley-VCH. D. Poyner, M.G. Wheatley (Eds.).
35. Kenakin T. Efficacy as a vector: The relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 2004, 65:2-11.
36. Kenakin T., Onaran O. The ligand paradox between affinity and efficacy: Can you be there and not make a difference?. Trends Pharmacol. Sci. 2002, 23:275-280.
37. Kennedy C., Henderson G. Chronic exposure to morphine does not induce dependence at the level of the calcium current in human SH-SY5Y cells. Neuroscience 1992, 49:937-944.
38. Kuszak A.J., Pitchiaya S., Anand J.P., Mosberg H.I., Walter N.G., Sunahara R.K. Purification and functional reconstitution of monomeric mu-opioid receptors: Allosteric modulation of agonist binding by Gi2. J. Biol. Chem. 2009, 284:26732-26741.
39. Labrecque J., Wong R.S., Fricker S.P. A time-resolved fluorescent lanthanide (Eu)-GTP binding assay for chemokine receptors as targets in drug discovery. Meth. Mol. Biol. 2009, 552:153-169.
40. Levitt E.S., Clark M.J., Jenkins P.M., Martens J.R., Traynor J.R. Differential effect of membrane cholesterol removal on mu- and delta-opioid receptors: A parallel comparison of acute and chronic signaling to adenylyl cyclase. J. Biol. Chem. 2009, 284:22108-22122.
41. Li J., Chen C., Huang P., Liu-Chen L.-Y. Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat μ-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation. Mol. Pharmacol. 2001, 60:1064-1075.
42. Li J., Huang P., Chen C., de Reil J.K., Weinstein H., Liu-Chen L.-Y. Constitutive activation of the mu opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression. Biochemistry 2001, 40:12039-12050.
43. Lin H., Saisch S.G., Strange P.G. Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor. Br. J. Pharmacol. 2006, 149:291-299.
44. Liu J.-G., Prather P.L. Chronic exposure to μ-opioid agonists produces constitutive activation of the μ-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol. Pharmacol. 2001, 60:53-62.
45. Liu J.G., Ruckle M.B., Prather P.L. Constitutively active μ-opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist [D-Ala2, N-MePhe4, Gly-ol5]enkephalin. J. Biol. Chem. 2001, 276:37779-37786.
46. + ions in rat sympathetic neurons. Mol. Pharmacol. 2010, 77:804-817.
47. Neilan C.L., Akil H., Woods J.H., Traynor J.R. Constitutive activity of the δ-opioid receptor expressed in C6 glioma cells: Identification of non-peptide δ-inverse agonists. Br. J. Pharmacol. 1999, 128:556-562.
48. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol. Pharmacol. 1998, 54:1064-1072.
49. Raehal K.M., Lowery J.J., Bhamidipati C.M., Paolino R.M., Blair J.R., Wang D., Sadee W., Bilsky E.J. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J. Pharmacol. Exp. Ther. 2005, 313:1150-1162.
50. Reinsheid R.K., Kim J., Zeng J., Civelli O. High-throughput real-time monitoring of Gs-coupled receptor activation in intact cells using cyclic-nucleotide gated channels. Eur. J. Pharmacol. 2003, 478:27-34.
51. Roberts D.J., Strange P.G. Mechanisms of inverse agonist action at D2 dopamine receptors. Br. J. Pharmacol. 2005, 145:34-42.
52. Rosenbaum D.M., Rasmussen S.G., Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature 2009, 459:356-363.
53. + channels in adult rat sympathetic neurons. J. Physiol. 1998, 513:761-773.
54. Sadana R., Dessauer C.W. Physiological roles for G protein-regulated adenylyl cyclase isoforms: Insights from knockout and overexpression studies. Neurosignals 2009, 17:5-22.
55. Sadee W., Wang D., Bilsky E.J. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci. 2005, 76:1427-1437.
56. Sadja R., Alagem N., Reuveny E. Graded contribution of the Gβγ binding domains to GIRK channel function. Proc. Natl. Acad. Sci. USA 2002, 99:10783-10788.
57. Sally E.J., Xu H., Dersch C.M., Hsin L.-W., Chang L.-T., Prisinzano T.E., Simpson D.S., Giuvelis D., Rice K.C., Jacobson A.E., Cheng K., Bilsky E.J., et al. Identification of a novel "almost neutral" μ-opioid receptor antagonist in CHO cells expressing the cloned μ-opioid receptor. Synapse 2010, 64:280-288.
58. Selley D.E., Nestler E.J., Brievogel C.S., Childers S.R. Opioid receptor-coupled G proteins in rat locus coeruleus membranes: Decrease in activity after chronic morphine treatment. Brain Res. 1997, 746:10-18.
59. 35 S]-GTPγS binding in mMOR-CHO cells and rat thalamus. J. Pharmacol. Exp. Ther. 1998, 285:496-505.
60. Smit M.J., Vischer H.F., Bakker R.A., Jongejan A., Timmerman H., Pardo L., Leurs R. Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. Annu. Rev. Pharmacol. Toxicol. 2007, 47:53-87.
61. Sternweis P.C., Robishaw J.D. Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. J. Biol. Chem. 1984, 259:13806-13813.
62. Szekeres P.G., Traynor J.R. Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: Characterization of agonist and inverse agonist effects. J. Pharmacol. Exp. Ther. 1997, 283:1276-1284.
63. 35 S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 1995, 47:848-854.
64. Vincent P., Gervasi N., Zhang J. Real-time monitoring of cyclic nucleotide signalling in neurons using genetically encoded FRET probes. Brain Cell Biol. 2008, 36:3-17.
65. Walwyn W., Evans C.J., Hales T.G. β-Arrestin and c-Src regulate the constitutive activity and recycling of μ-opioid receptors in dorsal root ganglion neurons. J. Neurosci. 2007, 27:5092-5104.
66. Wang Z., Bilsky E.J., Porreca F., Sadee W. Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci. 1994, 54:339-350.
67. Wang D., Raehal K.M., Bilsky E.J., Sadee W. Inverse agonists and neutral antagonists at μ opioid receptor (MOR): Possible role of basal receptor signaling in narcotic tolerance. J. Neurochem. 2001, 77:1590-1600.
68. Wang D., Raehal K.M., Lin E.T., Lowery J.J., Keiffer B.L., Bilsky E.J., Sadee W. Basal signalling activity of μ opioid receptor in mouse brain: Role in narcotic dependence. J. Pharmacol. Exp. Ther. 2004, 308:512-520.
69. Wang D., Sun X., Sadee W. Different effects of opioid antagonists on μ-, δ-, and κ-opioid receptors with and without agonist pretreatment. J. Pharmacol. Exp. Ther. 2007, 321:544-552.
70. Watts V.J., Neve K.A. Sensitization of adenylate cyclase by Gαi/o-coupled receptors. Pharmacol. Ther. 2005, 106:405-421.
71. Williams J.T., Christie M.J., Manzoni O. Cellular and synaptic adaptations mediating opioid withdrawal. Physiol. Rev. 2001, 81:299-343.
72. Xu H., Partilla J.S., Wang X., Rutherford J.M., Tidgewell K., Prisinzano T.E., Bohn L.M., Rothman R.B. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) μ-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse 2007, 61:166-175.
73. Yao X.J., Velez Ruiz G., Whorton M.R., Rasmussen S.G.F., DeVree B.T., Deupi X., Sunahara R.K., Kobilka B. The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc. Natl. Acad. Sci. USA 2009, 106:9501-9506.